Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Ciceri, Fabio  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
F
Raj K, Eikema D-J, McLornan DP, Olavarria E, Blok H-J, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, et al. Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2018.
Beelen DWilhelm, Iacobelli S, Koster L, Eikema D-J, van Biezen A, Stölzel F, Ciceri F, Bethge W, Dreger P, Wagner-Drouet E-M, et al. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison. Bone Marrow Transplant. 2024.
G
Gurnari C, Robin M, Godley LA, Drozd-Sokołowska J, Włodarski MW, Raj K, Onida F, Worel N, Ciceri F, Carbacioglu S, et al. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023.
Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, Giaccone L, Grillo G, Bramanti S, Bernasconi P, et al. GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS. Transplant Cell Ther. 2021.
Nagler A, Labopin M, Dholaria B, Wu D, Choi G, Aljurf M, Ciceri F, Gedde-Dahl T, Meijer E, Niittyvuopio R, et al. Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplant Cell Ther. 2021.
Paviglianiti A, Ngoya M, Peña M, Boumendil A, Gulbas Z, Ciceri F, Bonifazi F, Russo D, Fegueux N, Stölzel F, et al. Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor. Bone Marrow Transplant. 2024.
H
Bazarbachi A, Labopin M, Angelucci E, Gulbas Z, Ozdoğu H, Arat M, de Rosa L, Pastano R, Pioltelli P, Montserrat R, et al. Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. Biol Blood Marrow Transplant. 2020.
Nagler A, Labopin M, Tischer J, Raiola AMaria, Kunadt D, Vydra J, Blaise D, Chiusolo P, Fanin R, Winkler J, et al. Haploidentical transplantation in primary refractory/relapsed secondary versus de novo AML: from the ALWP/EBMT. Blood Adv. 2024.
Manfredi F, Stasi L, Buonanno S, Marzuttini F, Noviello M, Mastaglio S, Abbati D, Potenza A, Balestrieri C, Cianciotti BClaudia, et al. Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR. Sci Adv. 2023;9(48):eadg8014.
Passweg JR, Baldomero H, Ciceri F, Corbacioglu S, de la Camara R, Dolstra H, Glass B, Greco R, McLornan DP, Neven B, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplant. 2023.
Gentner B, Tucci F, Galimberti S, Fumagalli F, De Pellegrin M, Silvani P, Camesasca C, Pontesilli S, Darin S, Ciotti F, et al. Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome. N Engl J Med. 2021;385(21):1929-1940.
Mastrangelo A, Monardo R, Galli L, Tomelleri A, Din CTassan, Canetti D, Messina E, Guffanti M, Danise A, Campochiaro C, et al. High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation. Eur J Clin Microbiol Infect Dis. 2023.
Mori G, Diotallevi S, Farina F, Lolatto R, Galli L, Chiurlo M, Acerbis A, Xue E, Clerici D, Mastaglio S, et al. High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies. Microorganisms. 2024;12(1).
Crocchiolo R, Fusco C, Andreani M, Rombolà G, Falco M, Vecchiato C, Garbarino L, Mele L, Mazzi AB, Picardi A, et al. Histocompatibility assessment in hematopoietic stem cell transplantation: recommendations from the Italian Association of Immunogenetics and Biology of Transplantation (Associazione Italiana di Immunogenetica e Biologia dei Trapianti - AIBT). Blood Transfus. 2023.
Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, et al. HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transplant. 2018.
Locafaro G, Amodio G, Tomasoni D, Tresoldi C, Ciceri F, Gregori S. HLA-G Expression on Blasts and Tolerogenic Cells in Patients Affected by Acute Myeloid Leukemia. J Immunol Res. 2014;2014:636292.
Noviello M, Lorentino F, Xue E, Racca S, Furnari G, Valtolina V, Campodonico E, Dvir R, Lupo-Stanghellini MTeresa, Giglio F, et al. Human herpesvirus 6-specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients. Blood Adv. 2023.
I
Santoro N, Labopin M, Ciceri F, van Lint MTeresa, Nasso D, Blaise D, Arcese W, Tischer J, Bruno B, Ehninger G, et al. Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia over 45 years of age. Cancer. 2019.
Dalle IAbou, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M, Neubauer A, Blaise D, Yakoub-Agha I, Salmenniemi U, et al. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2023.
Xue E, Scorpio G, Ruggeri A, Clerici D, Farina F, Campodonico E, Acerbis A, Fiore P, Bruno A, Carrabba MG, et al. Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: A single center experience. Curr Res Transl Med. 2023;71(3):103402.
Oltolini C, Greco R, Galli L, Clerici D, Lorentino F, Xue E, Stanghellini MTeresa Lup, Giglio F, Uhr L, Ripa M, et al. Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA-matching. Biol Blood Marrow Transplant. 2020.
Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B, Snowden JA, Tarte K, et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine. 2024;69:102476.
Marktel S, Scaramuzza S, Cicalese MPia, Giglio F, Galimberti S, Lidonnici MRosa, Calbi V, Assanelli A, Bernardo MEster, Rossi C, et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia. Nat Med. 2019.
K
Shimoni A, Labopin M, Lorentino F, van Lint MTeresa, Koc Y, Gulbas Z, Tischer J, Bruno B, Blaise D, Pioltelli P, et al. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia. 2018.
L
Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C, Canale S, Lopez ID, Morena F, Calabria A, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet. 2016.

Pages